Q&A: Lisa H. Butterfield, Elizabeth M. Jaffee, and Arlene H. Sharpe on the SITC-AACR Joint Workshop, "The Cancer Biology Underlying Immunotherapy-Induced Autoimmunity"

Cancer Immunol Res. 2021 Sep;9(9):997-998. doi: 10.1158/2326-6066.CIR-21-0337.


Overcoming the immune-related adverse events that limit the use of immune checkpoint therapies in some cases requires a better understanding of the biology of these events.